Guan Wen-Long, Qiu Miao-Zhen, He Cai-Yun, Yang Li-Qiong, Jin Ying, Wang Zhi-Qiang, Li Yu-Hong, Xu Rui-Hua, Wang Feng-Hua
State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
State Key Laboratory of Oncology in South China, Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Front Oncol. 2020 Nov 23;10:563407. doi: 10.3389/fonc.2020.563407. eCollection 2020.
mutation is associated with poor prognosis of colorectal cancer (CRC) patients, but the comparison of clinic-pathologic features between V600E and non-V600E mutation was not well-known in CRC patients. The aim of this study is to evaluate the clinical and pathological features, prognostic value of mutations in CRC. We conducted a retrospective study to characterize the clinical and pathological features and survival of patients with mutated CRC. Patients were classified according to status as mutation and non-V600E mutations. Difference of characteristics and survival between the two groups was analyzed. There was no significant difference in gender, family history, location of primary tumor, metastatic sites between patients with -V600E mutation and non-V600E mutations. Patients with V600E mutation were younger than those with non-V600E mutations ( = 0.002). Patients with mutation showed a poorer outcome than those with non-V600E mutations (23.1 vs. 49.9 months, respectively, = 0.0024). Lack of CDX2 expression was associated with worse prognosis (mOS: 9.4 m vs. not reached, respectively, = 0.016). Status of V600E mutation did not affect the mPFS and ORR of first-line or second-line treatment. mutation defines a distinct subgroup of CRC with worse prognosis. Lack of CDX2 expression is associated with poor OS. Status of V600E mutation did not affect the mPFS of first-line or second-line treatment.
突变与结直肠癌（CRC）患者的预后不良相关，但在CRC患者中，V600E突变与非V600E突变之间临床病理特征的比较尚不清楚。本研究的目的是评估CRC中突变的临床和病理特征及预后价值。我们进行了一项回顾性研究，以描述携带突变的CRC患者的临床和病理特征及生存情况。患者根据状态分为V600E突变和非V600E突变。分析两组之间特征和生存的差异。V600E突变患者与非V600E突变患者在性别、家族史、原发肿瘤位置、转移部位方面无显著差异。V600E突变患者比非V600E突变患者年轻（P = 0.002）。V600E突变患者的预后比非V600E突变患者差（分别为23.1个月和49.9个月，P = 0.0024）。CDX2表达缺失与更差的预后相关（中位总生存期：分别为9.4个月和未达到，P = 0.016）。V600E突变状态不影响一线或二线治疗的中位无进展生存期和客观缓解率。V600E突变定义了一个预后较差的CRC独特亚组。CDX2表达缺失与较差的总生存期相关。V600E突变状态不影响一线或二线治疗的中位无进展生存期。
